+

BR112022021551A2 - Métodos para cultivar células - Google Patents

Métodos para cultivar células

Info

Publication number
BR112022021551A2
BR112022021551A2 BR112022021551A BR112022021551A BR112022021551A2 BR 112022021551 A2 BR112022021551 A2 BR 112022021551A2 BR 112022021551 A BR112022021551 A BR 112022021551A BR 112022021551 A BR112022021551 A BR 112022021551A BR 112022021551 A2 BR112022021551 A2 BR 112022021551A2
Authority
BR
Brazil
Prior art keywords
cells
methods
aspects
medium
engineered
Prior art date
Application number
BR112022021551A
Other languages
English (en)
Inventor
Kumar Vodnala Suman
Langland Eil Robert
P Restifo Nicholas
Original Assignee
Lyell Immunopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyell Immunopharma Inc filed Critical Lyell Immunopharma Inc
Publication of BR112022021551A2 publication Critical patent/BR112022021551A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)

Abstract

MÉTODOS PARA CULTIVAR CÉLULAS. A presente invenção refere-se a métodos para cultivar células, por exemplo, células pluripotentes, células multipotentes e/ou células imunes (por exemplo, células T, células NK e/ou TILs) em um meio compreendendo pelo menos cerca de 5 mM íon potássio, em que o meio não é hipertônico. Em alguns aspectos, o meio é hipotônico. Em alguns aspectos, os métodos divulgados neste documento aumentam o número de células menos diferenciadas na população de células. Em alguns aspectos, as células cultivadas são engenheiradas, por exemplo, para compreender um receptor de antígeno quimérico ou um receptor de células T engenheiradas. Em alguns aspectos, as células são administradas a um indivíduo em necessidade do mesmo.
BR112022021551A 2020-04-28 2021-04-28 Métodos para cultivar células BR112022021551A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063016907P 2020-04-28 2020-04-28
PCT/US2021/029762 WO2021222479A1 (en) 2020-04-28 2021-04-28 Methods for culturing cells

Publications (1)

Publication Number Publication Date
BR112022021551A2 true BR112022021551A2 (pt) 2023-01-03

Family

ID=75954306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021551A BR112022021551A2 (pt) 2020-04-28 2021-04-28 Métodos para cultivar células

Country Status (11)

Country Link
US (1) US12365871B2 (pt)
EP (1) EP4143300A1 (pt)
JP (1) JP2023524047A (pt)
KR (1) KR20230017786A (pt)
CN (1) CN115768879A (pt)
AU (1) AU2021265797A1 (pt)
BR (1) BR112022021551A2 (pt)
CA (1) CA3158133A1 (pt)
IL (1) IL297751A (pt)
MX (1) MX2022013599A (pt)
WO (1) WO2021222479A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115605503A (zh) 2020-03-20 2023-01-13 莱尔免疫制药股份有限公司（Us） 新的重组细胞表面标志物
BR112022021551A2 (pt) 2020-04-28 2023-01-03 Lyell Immunopharma Inc Métodos para cultivar células
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
CA3234825A1 (en) * 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods of generating cells
WO2023076577A2 (en) * 2021-10-28 2023-05-04 Memorial Sloan-Kettering Cancer Center Methods for modulating cell pluripotency and self-renewal property
KR20230127938A (ko) 2022-02-25 2023-09-01 주식회사 강스템바이오텍 무혈청배지를 이용한 줄기세포 배양 방법
WO2023163560A1 (ko) 2022-02-25 2023-08-31 주식회사 강스템바이오텍 마이크로캐리어를 이용한 줄기세포 배양 방법
CN114958737B (zh) * 2022-03-28 2024-02-09 苏州系统医学研究所 一种干性记忆t细胞的体外扩增方法及其应用
IT202200010535A1 (it) * 2022-05-20 2023-11-20 Humanitas Mirasole Spa Cellule t cd8+ potenziate per l'immunoterapia del cancro

Family Cites Families (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86278A (en) 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
EP0460065B1 (en) 1989-02-21 1994-08-31 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION A process for the generation of proliferating cd4 lymphocytes
EP0475972A4 (en) 1989-05-15 1992-05-20 E.I. Du Pont De Nemours And Company Improved culture of human tumor-infiltrating lymphocytes by combining gas permeable bags and a primary culture container
IT1261180B (it) 1993-02-10 1996-05-09 Metodo di propagazione in vitro di cellule til.
WO1997012244A1 (en) 1995-09-27 1997-04-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining t-cell profiles of immunocompromised subjects
ES2177964T3 (es) 1996-03-30 2002-12-16 Science Park Raf S P A Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
US20020081635A1 (en) 2000-05-11 2002-06-27 Thomas Terry E. Novel antibody compositions for preparing enriched T cell preparations
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
EP1432431B1 (en) 2001-10-04 2017-05-10 Genetics Institute LLC Methods and compositions for modulating interleukin-21 activity
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US7381405B2 (en) 2002-10-15 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
EP1558085A4 (en) 2002-10-15 2006-12-06 Us Gov Health & Human Serv METHOD FOR THE PRODUCTION OF LYMPHOCYTES EXPRESSING INTERLEUKIN-2 AND THEIR USE IN THE TREATMENT OF CANCER
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
ES2601896T3 (es) 2004-11-24 2017-02-16 Fred Hutchinson Cancer Research Center Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales
US8735157B2 (en) 2005-06-09 2014-05-27 Gal Markel CEACAM1 mediated protective immunity
CA2623735A1 (en) 2005-09-30 2007-04-12 Takara Bio Inc. Method for production of t cell population
JPWO2007037544A1 (ja) 2005-09-30 2009-04-16 国立大学法人京都大学 制御性ｔ細胞の製造を向上させる薬剤のスクリーニング方法の開発、及び免疫抑制性のマクロライド系抗生剤を用いる制御性ｔ細胞の製造方法
WO2007071409A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating colon cancer
US8211424B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating malignant melanoma
DK2069381T3 (da) 2006-09-13 2016-03-14 Univ Columbia Midler og fremgangsmåder til udløsning af anti-tumorimmunrespons
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
EP2102241A2 (en) 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
FR2911346B1 (fr) 2007-01-12 2012-12-07 Ct Hospitalier Universitaire De Nantes Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til
EP2140247B1 (en) 2007-04-26 2012-06-27 The Ludwig Institute for Cancer Research Method for modulating activity of t lymphocytes
US20120114675A1 (en) 2008-11-13 2012-05-10 Graca Luis Ricardo Simoes Da Silva Foxp3+ natural killer t-cells and the treatment of immune related diseases
US8883500B2 (en) 2008-12-05 2014-11-11 Northeastern University Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US9512401B2 (en) 2010-10-01 2016-12-06 Board Of Regents, The University Of Texas System B and T lymphocyte attenuator marker for use in adoptive T-cell therapy
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP2689010B1 (en) 2011-03-23 2020-11-18 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
RU2011130448A (ru) 2011-07-22 2013-01-27 Зао "Евроген" Методы и наборы для увеличения разнообразия т-клеток
CN103906516A (zh) 2011-09-21 2014-07-02 干细胞医药有限公司 用于增强T细胞介导的免疫应答的β-内酰胺化合物
EP2768939B1 (en) 2011-10-21 2016-08-17 Cell Medica Limited Device for the aseptic expansion of cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
JP2015509382A (ja) 2012-03-07 2015-03-30 チルドレンズ メディカル センター コーポレーション 組織構築体およびその使用
WO2013167136A1 (en) 2012-05-08 2013-11-14 Herlev Hospital Improving adoptive cell therapy with interferon gamma
IL269270B (en) 2012-08-20 2022-07-01 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
WO2014039044A1 (en) 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
WO2015039100A1 (en) 2013-09-16 2015-03-19 The Trustees Of The University Of Pennsylvania Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
US9886736B2 (en) 2014-01-20 2018-02-06 Nvidia Corporation Selectively killing trapped multi-process service clients sharing the same hardware context
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
ES2777304T3 (es) 2014-02-21 2020-08-04 Colmmune Inc Células TSCM y métodos de uso
MX374472B (es) 2014-03-20 2025-03-06 H Lee Moffitt Cancer Ct & Res Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
US10016421B2 (en) 2014-04-05 2018-07-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
US10975353B2 (en) 2014-06-10 2021-04-13 Polybiocept Gmbh Culture medium for cellular immunotherapy
UA123821C2 (uk) 2014-06-11 2021-06-09 Полібіосепт Гмбх Композиція для експансії лімфоцитів in vitro
US11585806B2 (en) 2014-06-13 2023-02-21 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
EP3194577A4 (en) 2014-09-17 2018-04-04 The Johns Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
EP3194433B1 (en) 2014-09-19 2019-05-22 City of Hope Costimulatory chimeric antigen receptor t cells targeting il13r 2
CA2963362A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
WO2016081518A2 (en) 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
US10815457B2 (en) 2014-11-24 2020-10-27 University Of Pittsburgh Of The Commonwealth Systems Of Higher Education Active CXCR4+ immune cells and methods for their production and use
EP3226898A4 (en) 2014-12-05 2018-07-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bromodomain inhibitor as adjuvant in cancer immunotherapy
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
EP4137151A1 (en) 2015-04-27 2023-02-22 Cancer Research Technology Ltd. Method
FR3040396A1 (fr) 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
AU2016297605A1 (en) 2015-07-21 2018-02-15 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
EP3328399B1 (en) 2015-07-31 2023-12-27 Regents of the University of Minnesota Modified cells and methods of therapy
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
TWI873491B (zh) 2015-10-20 2025-02-21 美商凱特製藥公司 製備用於ｔ細胞治療之ｔ細胞的方法
RU2767209C2 (ru) 2015-10-23 2022-03-16 Еурека Терапьютикс, Инк. Химерные конструкции антитело/т-клеточный рецептор и их применения
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
WO2017087768A1 (en) 2015-11-18 2017-05-26 Duke University Targeted delivery of interleukin-10 to tumor infiltrating lymphocytes
EP3397756B1 (en) 2015-12-30 2023-03-08 Novartis AG Immune effector cell therapies with enhanced efficacy
TWI808934B (zh) 2015-12-31 2023-07-21 美商伯克利之光生命科技公司 經工程化以表現促發炎多肽之腫瘤浸潤細胞
WO2017123911A1 (en) 2016-01-15 2017-07-20 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
US11096964B2 (en) 2016-01-20 2021-08-24 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
US20180135011A1 (en) 2017-03-13 2018-05-17 Berkeley Lights, Inc. Selection and cloning of t lymphocytes in a microfluidic device
GB201608060D0 (en) 2016-05-09 2016-06-22 Univ Birmingham Method of culturing T cells
WO2017210677A1 (en) 2016-06-03 2017-12-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1α) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS)
CA3028813A1 (en) 2016-06-24 2017-12-28 Mcmaster University Adoptive cell transfer and oncolytic virus combination therapy
WO2018009894A1 (en) 2016-07-07 2018-01-11 Iovance Biotherapeutics, Inc. Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
EP3500298A4 (en) 2016-08-17 2020-04-01 University Health Network REGULATION OF T LYMPHOCYTES ASSOCIATED WITH A TUMOR
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
EP3515461A1 (en) 2016-09-23 2019-07-31 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory t cells
AU2017337147A1 (en) 2016-09-30 2019-03-21 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
JP2019532953A (ja) 2016-09-30 2019-11-14 ノバルティス アーゲー 増強された有効性を有する免疫エフェクター細胞治療
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
GB2605540B (en) 2016-10-18 2022-12-21 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018072105A1 (zh) 2016-10-19 2018-04-26 中山大学 一种干细胞样记忆性t细胞体外诱导剂及方法
LT3532607T (lt) 2016-10-26 2024-05-10 Iovance Biotherapeutics, Inc. Kriokonservuotų naviką infiltruojančių limfocitų restimuliacija
CA3041831A1 (en) 2016-10-27 2018-05-03 Intima Bioscience, Inc. Viral methods of making genetically modified cells
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018081784A1 (en) 2016-10-31 2018-05-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for expanding immune cells for immunotherapy
WO2018094167A1 (en) 2016-11-17 2018-05-24 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
JP7098615B2 (ja) 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
US11157880B2 (en) 2017-01-09 2021-10-26 International Business Machines Corporation Enforcement of services agreement and management of emotional state
CN106834228B (zh) 2017-01-17 2021-03-23 上海新长安生物科技有限公司 一种体外扩增cd8+t细胞及其细胞亚群的方法
WO2018145033A1 (en) * 2017-02-03 2018-08-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US20200087625A1 (en) 2017-03-30 2020-03-19 Dennis A. Carson Methods for isolating, expanding and administering cancer specific cd8+ t cells
AU2018241849B2 (en) 2017-03-31 2023-06-22 Boehringer Ingelheim International Gmbh Perfusion medium
CN110603044B (zh) 2017-03-31 2024-11-05 小利兰·斯坦福大学托管委员会 通过抑制或调节t细胞受体信号转导治疗t细胞耗竭的方法
GB201705504D0 (en) 2017-04-05 2017-05-17 Adaptimmune Ltd Methods of isolating naïve regulatory T cells
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
US20200377855A1 (en) 2017-05-05 2020-12-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rapid method for the culture of tumor infiltrating lymphocytes
AU2018266202C1 (en) 2017-05-10 2025-05-08 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
WO2019014684A1 (en) 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
WO2019018603A2 (en) 2017-07-19 2019-01-24 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
MA49981A (fr) 2017-08-09 2020-06-17 Juno Therapeutics Inc Procédés et compositions de préparation de cellules génétiquement modifiées
WO2019040590A1 (en) 2017-08-22 2019-02-28 Translate Bio Ma, Inc. MODULATION OF THE EXPRESSION OF SOLUBLE FAS
US11597739B2 (en) 2017-08-24 2023-03-07 The Royal Institution For The Advancement Of Learning/Mcgill University Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP)
KR102850471B1 (ko) 2017-09-20 2025-08-27 넥스이뮨, 인크. 입양 요법을 위한 항원-특이적 t 세포를 포함하는 세포 조성물
US20210130776A1 (en) 2017-09-29 2021-05-06 The Broad Institute, Inc. Methods and compositions for modulating suppression of lymphocyte activity
EP4488366A3 (en) 2017-10-18 2025-03-12 Vivia Biotech, S.L. Bite-activated car-t cells
US20190127694A1 (en) 2017-10-27 2019-05-02 Augusta University Research Institute, Inc. Induced Stem Memory T-Cells and Methods of Use Thereof
EP3701041A4 (en) 2017-10-27 2021-11-17 The Trustees of The University of Pennsylvania METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH DEPLETED T-LYMPHOCYTES
CN111801415A (zh) 2017-11-06 2020-10-20 路德维格癌症研究院 扩增淋巴细胞的方法
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
US20200277573A1 (en) 2017-11-17 2020-09-03 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
JP7565795B2 (ja) 2017-12-15 2024-10-11 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136456A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
EP3737695A1 (en) 2018-01-10 2020-11-18 The Board of Trustees of the Leland Stanford Junior University Compositions and methods of expansion of t cell populations
GB201801067D0 (en) 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2019191501A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Use of histone modifiers to reprogram effector t cells
MX2020010264A (es) 2018-03-29 2020-11-06 Iovance Biotherapeutics Inc Procesos para la produccion de linfocitos infiltrantes en tumor y usos de los mismos en inmunoterapia.
WO2019201970A1 (en) 2018-04-19 2019-10-24 University Of Copenhagen A mertk ligand for adoptive t cell cancer therapy
AU2019260656B2 (en) * 2018-04-24 2025-08-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
TW202446952A (zh) 2018-04-27 2024-12-01 美商艾歐凡斯生物治療公司 腫瘤浸潤性淋巴細胞之基因編輯和彼於免疫治療之用途
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019222763A1 (en) 2018-05-18 2019-11-21 Children's National Medical Center System of cell expansion and methods of using the same
US20210207095A1 (en) 2018-06-01 2021-07-08 Monash University Methods of activating cells via ptp 1b inhibition
US20210230543A1 (en) 2018-06-05 2021-07-29 H.Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells comprising protein l for expanding immune cells for immunotherapy
WO2019236681A1 (en) 2018-06-05 2019-12-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rapid production, expansion, and increased purity of car-t cells using beads with protein l
WO2019241536A1 (en) 2018-06-14 2019-12-19 Lixte Biotechnology, Inc. Oxabicycloheptanes for enhancing car t cell function
CN112739350A (zh) 2018-07-27 2021-04-30 诺德韦斯特生物科学有限公司 采用过继性t细胞免疫疗法治疗肿瘤患者的方法
WO2020025706A1 (en) 2018-07-31 2020-02-06 Polybiocept Gmbh Production and selection of tumor uber reactive immune cells (turics)
WO2020028400A1 (en) 2018-07-31 2020-02-06 Washington University Use of interleukin-7 and chimeric antigen receptor (car)-bearing immune effector cells for treating tumor
JP2021534747A (ja) 2018-08-22 2021-12-16 セレクト バイオセラピューティクス リミテッド アポトーシス感受性細胞のモジュレーション
SG11202101455TA (en) 2018-08-28 2021-03-30 Hutchinson Fred Cancer Res Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
LT3844267T (lt) 2018-08-31 2025-10-10 Chimerinių antigenų receptorius ekspresuojančių ląstelių gaminimo metodai
KR20210064269A (ko) 2018-09-20 2021-06-02 이오반스 바이오테라퓨틱스, 인크. 동결보존된 종양 샘플로부터의 til의 확장
CA3116406A1 (en) 2018-09-24 2020-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Culture of tumor infiltrating lymphocytes from tumor digest
CN113056276A (zh) 2018-10-18 2021-06-29 得克萨斯大学体系董事会 用于产生组织驻留记忆样t细胞的方法及其用途
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
US20220002674A1 (en) 2018-10-31 2022-01-06 Bellicum Pharmaceuticals, Inc. T cells with suicide switch
EP3873539A4 (en) 2018-10-31 2023-01-18 The Children's Hospital of Philadelphia LYMPH-BASED T-CELLS FOR DIAGNOSTIC AND THERAPEUTIC USE
JP2022512915A (ja) 2018-11-05 2022-02-07 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
MX2021004775A (es) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
CR20210295A (es) 2018-11-05 2021-07-09 Iovance Biotherapeutics Inc Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
CA3118634A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
MX2021005372A (es) 2018-11-08 2021-09-14 Neximmune Inc Composiciones de linfocitos t con propiedades fenotípicas mejoradas.
WO2020116606A1 (ja) 2018-12-06 2020-06-11 キリンホールディングス株式会社 Ｔ細胞又はｎｋ細胞の製造方法、ｔ細胞又はｎｋ細胞の培養用培地、ｔ細胞又はｎｋ細胞の培養方法、未分化ｔ細胞の未分化状態を維持する方法及びｔ細胞又はｎｋ細胞の増殖促進剤
JP7710372B2 (ja) 2018-12-19 2025-07-18 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
CA3125762A1 (en) 2019-01-10 2020-07-16 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
KR20200092155A (ko) 2019-01-24 2020-08-03 울산대학교 산학협력단 종양침윤림프구를 유효성분으로 포함하는 삼중음성 유방암 예방 또는 치료용 조성물
US20220017863A1 (en) 2019-02-08 2022-01-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Sirt2-ablated chimeric t cells
CA3131305A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220177839A1 (en) 2019-03-05 2022-06-09 Shanghai Sinobay Biotechnology Co., Ltd. Composition, culture medium and method for inducing and/or amplifying tscm in vitro
CU24712B1 (es) 2019-03-15 2024-07-10 Centre Hospitalier Univ Vaudois Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
MA55562A (fr) 2019-04-05 2022-02-09 2Seventy Bio Inc Production de cellules car-t anti-bcma
WO2020219812A1 (en) 2019-04-26 2020-10-29 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
AR118859A1 (es) 2019-05-08 2021-11-03 Neon Therapeutics Inc Composiciones y métodos de fabricación de células t
CN110157680A (zh) 2019-05-08 2019-08-23 浙江大学 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
KR102081585B1 (ko) 2019-05-16 2020-02-26 (주)녹십자셀 활성화 림프구 및 이의 제조 방법
KR20220042353A (ko) 2019-06-24 2022-04-05 칠드런＇스 하스피틀 로스 앤젤레스 사람 흉선 세포 생성 및 t 세포 기능을 증진시키기 위한 bcl11b 과발현
EP3990011A4 (en) 2019-06-24 2023-11-01 H. Lee Moffitt Cancer Center & Research Institute, Inc. PEPTIDE-BASED SCREENING METHOD FOR IDENTIFYING NEO-ANTIGENS FOR USE WITH TUMOR-INFILTRATING LYMPHOCYTES
KR20220073729A (ko) 2019-07-17 2022-06-03 케이스 웨스턴 리저브 유니버시티 Hiv 감염 치료용 장기 생존 t 세포
GB201910605D0 (en) 2019-07-24 2019-09-04 Immetacyte Ltd Tumour infltracting lymphocyte therapy amd uses thereo
US20220268762A1 (en) 2019-07-28 2022-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods, systems, and computer-readable media for predicting a cancer patient's response to immune-based or targeted therapy
US20220331360A1 (en) 2019-08-07 2022-10-20 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services T cells having enhanced anti-tumor activity
US20220305038A1 (en) 2019-08-16 2022-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
MX2022002527A (es) 2019-09-03 2022-04-01 Allogene Therapeutics Inc Metodos de preparacion de linfocitos t para la terapia con linfocitos t.
JP2022549007A (ja) 2019-09-24 2022-11-22 ニューリックス セラピューティクス，インコーポレイテッド 養子細胞療法に使用するためのｃｂｌ阻害剤および組成物
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
JP2022553389A (ja) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
US20240376428A1 (en) 2019-11-25 2024-11-14 KSQ Therapeutics, Inc. Methods for activation and expansion of tumor infiltrating lymphocytes
AU2020391231A1 (en) 2019-11-27 2022-07-14 Turnstone Biologics Corp. Method of producing tumor-reactive T cell composition using modulatory agents
EP4073236A1 (en) 2019-12-11 2022-10-19 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
KR20220119080A (ko) 2019-12-18 2022-08-26 씨비아이오 에이/에스 치료용 종양-침윤 림프구들 배양을 위한 개선된 방법
IL294098A (en) 2019-12-20 2022-08-01 Instil Bio Uk Ltd Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
US20230036952A1 (en) 2020-01-07 2023-02-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using induced pluripotent stem cells
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
US20230108584A1 (en) 2020-02-28 2023-04-06 KSQ Therapeutics, Inc, Methods for activation and expansion of tumor infiltrating lymphocytes
CN111440773B (zh) 2020-04-07 2023-03-14 上海交通大学 一种t细胞体外嵌合抗原受体改造及扩增的优化培养方法
BR112022021551A2 (pt) 2020-04-28 2023-01-03 Lyell Immunopharma Inc Métodos para cultivar células
KR20230124913A (ko) 2020-11-23 2023-08-28 라이엘 이뮤노파마, 인크. 면역 세포를 배양하기 위한 방법
JP2024509095A (ja) 2021-02-25 2024-02-29 ライエル・イミュノファーマ・インコーポレイテッド 細胞の培養方法
CN117083376A (zh) * 2021-02-25 2023-11-17 莱尔免疫制药公司 用于培养细胞的方法
CA3234825A1 (en) * 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods of generating cells
CN118451098A (zh) * 2021-10-28 2024-08-06 莱尔免疫制药公司 培养表达c-jun的细胞的方法
CN118308300A (zh) * 2024-04-16 2024-07-09 苏州纽博立科技有限公司 一种用于t细胞体外培养的细胞培养基及其制备方法和应用

Also Published As

Publication number Publication date
CN115768879A (zh) 2023-03-07
WO2021222479A1 (en) 2021-11-04
MX2022013599A (es) 2023-01-24
AU2021265797A1 (en) 2022-12-08
US12365871B2 (en) 2025-07-22
CA3158133A1 (en) 2021-11-04
IL297751A (en) 2022-12-01
KR20230017786A (ko) 2023-02-06
US20210332326A1 (en) 2021-10-28
JP2023524047A (ja) 2023-06-08
WO2021222479A9 (en) 2022-08-11
EP4143300A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
BR112022021551A2 (pt) Métodos para cultivar células
Shaikh et al. Mouse bone marrow VSELs exhibit differentiation into three embryonic germ lineages and germ & hematopoietic cells in culture
Ahmed et al. Human stem cell-like memory T cells are maintained in a state of dynamic flux
Tresoldi et al. Stability of human rapamycin-expanded CD4+ CD25+ T regulatory cells
Haase et al. Generation of non-transgenic iPS cells from human cord blood CD34+ cells under animal component-free conditions
Swamynathan et al. Are serum-free and xeno-free culture conditions ideal for large scale clinical grade expansion of Wharton’s jelly derived mesenchymal stem cells? A comparative study
Kassem Stem cells: Potential therapy for age‐related diseases
MY189819A (en) Genetically modified cells and uses thereof
MX2021013219A (es) Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos.
BRPI0618486A2 (pt) uso de células progenitoras multipotentes em adultos
BR112015019603A2 (pt) Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
Zafranskaya et al. In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients
BR112019009746A2 (pt) ensaio de células-tronco pluripotentes
Aguiar et al. Differentiation of equine induced pluripotent stem cells into a keratinocyte lineage
Sun et al. Reconstitution of gametogenesis in vitro: meiosis is the biggest obstacle
Pereira et al. Human articular chondrocytes regulate immune response by affecting directly T cell proliferation and indirectly inhibiting monocyte differentiation to professional antigen-presenting cells
Blunt et al. Phenotypic characterization of bovine memory cells responding to mycobacteria in IFNγ enzyme linked immunospot assays
El-Kehdy et al. Immunoprofiling of Adult‐Derived Human Liver Stem/Progenitor Cells: Impact of Hepatogenic Differentiation and Inflammation
HRP20170216T1 (hr) Populacija ljudskih matičnih stanica vrata maternice i njihova uporaba
MX2022001383A (es) Celulas para inmunoterapia mejorada y usos de las mismas.
WO2022232797A3 (en) Virus-specific immune cells expressing chimeric antigen receptors
Bačenková et al. Analysis of same selected immunomodulatory properties of chorionic mesenchymal stem cells
de Souza et al. Generation of primordial germ cell-like cells from iPSCs derived from turner syndrome patients
BR112016018826A8 (pt) anticorpo purificado, ou fragmento de ligação de antígeno, método para a identificação de uma população de células de esperma de mamífero portadoras de cromossomo x, e método in vitro para distorcer uma proporção entre os sexos
WO2022164807A3 (en) Genetically modified hepatocyte populations

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载